Sutro Biopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
35.0%projected annual EPS growth
Analyst Coverage
12analysts covering
FY EPS (est.)
-$7.80next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Marketable Securities Quarterly202.6MTarget: Sufficient to fund operations into at least Q2 2028
Quarterly Collaboration Revenue Quarterly14.5M
Quarterly Operating Expenses (R&D and G&A) Quarterly44.1M
Watch Items
- STRO-004 Phase 1 Dose-Escalation Trial Initial DataTrigger: Initial safety, pharmacokinetic, and early activity data readoutAction: Evaluate clinical profile, depth/durability of response, and platform validation in mid-2026
- STRO-006 (ITGB6 ADC) IND SubmissionTrigger: IND filing with the FDAAction: Monitor regulatory clearance to transition the program into clinical development in 2026
- STRO-227 (PTK7 Dual-Payload ADC) IND SubmissionTrigger: IND filing with the FDAAction: Track regulatory progress for the first wholly-owned dual-payload program in late 2026
- Astellas Collaboration MilestonesTrigger: Clinical advancement of partnered dual-payload iADCsAction: Monitor clinical progression of TROP2-targeted iADC (ASP2998) and subsequent milestone payments
Research as of 19 Jun 2026